Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07209267) titled 'Baricitinib Curative Repression of HIV-1' on Oct. 2.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Emory University
Condition:
HIV Infection
HIV
Intervention:
Drug: Antiretroviral Therapy (ART)
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: November 2025
Target Sample Size: 20
Countries of Recruitment:
United States
To know more, visit https://clinicaltrials.gov/study/NCT07209267
Published by HT Digital Content Services with permission from Hea...